08.31.15
Jacksonville, Fla.-based NovaBone Products LLC, a biologics company, has earned U.S. Food and Drug Administration approval for its Macroform MIS Delivery System. The system is designed for use in minimally invasive orthopedic procedures.
Using Macroform, surgeons can directly deliver bone marrow aspirate to a graft which is housed in a closed, ready to use minimally invasive cannula. The system was developed for surgeons who require controlled and precise delivery of bone grafting material to surgical sites that are not readily accessible.
“The Macroform MIS Delivery System builds off the commercial success of the intuitively-designed collagen devices we have launched over the past several months,” said Dennis McBride, vice president of sales and marketing. “Moreover, NovaBone’s Macroform technology, which offers more bioactivity than any other competitive product, is now available in multiple formulations, and delivery options.”
NovaBone Products has announced release of six new collagen products in the last twelve months. The devices are based on the company’s regenerative medicine technology and core competencies in designing innovative and cost-effective medical devices that meet the demands of surgeons.
“We continue to reach milestones we have established,” said Art Wotiz, president of NovaBone Products. “Our team has done an excellent job in terms of both design and manufacturing of collagen products and creating a robust pipeline of products that harness the natural healing process of the body.”
NovaBone Products ‘ expertise is in bioactive glass design and manufacturing.
Using Macroform, surgeons can directly deliver bone marrow aspirate to a graft which is housed in a closed, ready to use minimally invasive cannula. The system was developed for surgeons who require controlled and precise delivery of bone grafting material to surgical sites that are not readily accessible.
“The Macroform MIS Delivery System builds off the commercial success of the intuitively-designed collagen devices we have launched over the past several months,” said Dennis McBride, vice president of sales and marketing. “Moreover, NovaBone’s Macroform technology, which offers more bioactivity than any other competitive product, is now available in multiple formulations, and delivery options.”
NovaBone Products has announced release of six new collagen products in the last twelve months. The devices are based on the company’s regenerative medicine technology and core competencies in designing innovative and cost-effective medical devices that meet the demands of surgeons.
“We continue to reach milestones we have established,” said Art Wotiz, president of NovaBone Products. “Our team has done an excellent job in terms of both design and manufacturing of collagen products and creating a robust pipeline of products that harness the natural healing process of the body.”
NovaBone Products ‘ expertise is in bioactive glass design and manufacturing.